Aligos Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
ALGS$3.95-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| June 30,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $18,661 | $36,997 |
| Restricted cash | 110 | 110 |
| Short-term investments | 104,284 | 19,942 |
| Other current assets | 4,889 | 5,092 |
| Total current assets | 127,944 | 62,141 |
| Operating lease right-of-use assets | 4,059 | 4,964 |
| Property and equipment, net | 2,063 | 2,362 |
| Other assets | 640 | 627 |
| Total assets | $134,706 | $70,094 |
| LIABILITIES AND | ||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $3,937 | $2,571 |
| Accrued liabilities | 12,209 | 15,557 |
| Operating lease liabilities, current | 3,502 | 3,422 |
| Finance lease liabilities, current | 38 | 36 |
| Deferred revenue, current | 579 | 151 |
| Total current liabilities | 20,265 | 21,737 |
| Operating lease liabilities, net of current portion | 3,216 | 4,795 |
| Finance lease liabilities, net of current portion | 122 | 122 |
| 2023 common warrants liability | 9,191 | 72,367 |
| Long term liability | 46 | 46 |
| Total liabilities | 32,840 | 99,067 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity (deficit): | ||
| Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively. | - | - |
| Common stock, $0.0001 par value; 115,800,000 shares and 20,800,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 6,151,274 and 3,864,436 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively. | 9 | 8 |
| Additional paid-in capital | 692,220 | 588,576 |
| Accumulated deficit | (590,783) | (618,008) |
| Accumulated other comprehensive income | 420 | 451 |
| Total stockholders’ equity (deficit) | 101,866 | (28,973) |
| Total liabilities and stockholders’ equity (deficit) | $134,706 | $70,094 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.